Aspect Biosystems raises $115M Series B for bioprinted tissue therapeutics targeting diabetes and metabolic disorders, led by ...
Galapagos is looking for a fresh start after a rough few years. The Belgian biotech has outlined plans to branch off into two ...
With schizophrenia trial success, LB Pharmaceuticals thinks about Phase 3 and next funding
A private startup looking to bring an old schizophrenia drug class to the US has released new Phase 2 data and aims to start ...
Jasper Therapeutics continued building out the data for a drug designed to treat irritable skin conditions, though the latest ...
Novo Nordisk is doubling down on its computational biotech partner Valo Health, expanding their collaboration from 11 ...
Maze Therapeutics has submitted its pitch for an initial public offering after disclosing a $115 million Series D, forging a ...
Sanofi has enlisted drug discovery company Alloy Therapeutics to develop an antisense oligonucleotide drug for a single, undisclosed central nervous system target.
Aetna is going after another pharmaceutical company for alleged price fixing. The health insurance provider ...
New anti-obesity drugs should meet a minimum level of weight loss to be considered for approval, the FDA said ...
Bayer’s Nexavar and Boehringer Ingelheim's Spiriva are among a handful of drugs with reduced US list prices for the new year, ...
This year's first radiopharmaceutical deal is slated to expand BWX Technologies’ presence in the North American nuclear tech ...
Eli Lilly joins FDA lawsuit over tirzepatide shortage listing, as Outsourcing Facilities Association challenges removal of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback